AI Article Synopsis
- Circulating microRNAs, specifically let-7a and miR-16, were studied as potential cancer biomarkers in patients with myelodysplastic syndrome (MDS) compared to healthy controls.
- The study found that levels of both miRNAs were significantly lower in MDS patients, and these levels were associated with patients' progression-free survival and overall survival rates.
- Let-7a, in particular, was identified as a strong independent predictor of overall survival, suggesting that measuring these miRNAs could serve as noninvasive prognostic markers for MDS patients.
Article Abstract
Circulating microRNAs (miRNAs) are potential biomarkers for cancer. We examined plasma levels of 2 miRNAs, let-7a and miR-16, in 50 patients with myelodysplastic syndrome (MDS) and 76 healthy persons using quantitative real-time PCR. Circulating levels of both miRNAs were similar among healthy controls but were significantly lower in MDS patients (P = .001 and P < .001, respectively). The distributions of these 2 miRNA levels were bimodal in MDS patients, and these levels were significantly associated with their progression-free survival and overall survival (both P < .001 for let-7a; P < .001 and P = .001 for miR-16). This association persisted even after patients were stratified according to the International Prognostic Scoring System. Multivariate analysis revealed that let-7a level was a strong independent predictor for overall survival in this patient cohort. These findings suggest that let-7a and miR-16 plasma levels can serve as noninvasive prognostic markers in MDS patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3293748 | PMC |
| http://dx.doi.org/10.1182/blood-2011-01-330704 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!